Autoantibodies Targeting Ficolin‐2 in Systemic Lupus Erythematosus Patients With Active Nephritis
Objective Systemic lupus erythematosus (SLE) is a multisystem inflammatory disease characterized by the production of various autoantibodies. The aim of this study was to investigate the presence of anti–ficolin‐2 antibodies in SLE patients and to evaluate the association between the levels of these...
Gespeichert in:
| Veröffentlicht in: | Arthritis care & research (2010) 2018-08, Vol.70 (8), p.1263-1268 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1268 |
|---|---|
| container_issue | 8 |
| container_start_page | 1263 |
| container_title | Arthritis care & research (2010) |
| container_volume | 70 |
| creator | Colliard, Sophie Jourde‐Chiche, Noémie Clavarino, Giovanna Sarrot‐Reynauld, Françoise Gout, Evelyne Deroux, Alban Fougere, Mélanie Bardin, Nathalie Bouillet, Laurence Cesbron, Jean‐Yves Thielens, Nicole M. Dumestre‐Pérard, Chantal |
| description | Objective
Systemic lupus erythematosus (SLE) is a multisystem inflammatory disease characterized by the production of various autoantibodies. The aim of this study was to investigate the presence of anti–ficolin‐2 antibodies in SLE patients and to evaluate the association between the levels of these autoantibodies, clinical manifestations, and disease activity.
Methods
This is a comparative study using a cohort of 165 SLE patients and 48 healthy subjects. SLE patients were further divided into 2 groups (low disease activity [SLE Disease Activity Index (SLEDAI) score ≤4, n = 88] and high disease activity [SLEDAI score >4, n = 77]). Clinical manifestations were defined according to the physician in charge. Active lupus nephritis (LN) was documented by kidney biopsy. Detection of anti–ficolin‐2 antibodies was performed by enzyme‐linked immunosorbent assay.
Results
Levels of anti–ficolin‐2 autoantibodies were significantly higher in SLE patients as compared to healthy subjects and associated with SLEDAI score. They were found to be positive in 61 of 165 SLE patients (37%). The presence of anti–ficolin‐2 antibodies was significantly related only to renal involvement, with a very high prevalence (86%) of anti–ficolin‐2 antibodies in SLE patients with active LN. Patients with active proliferative LN had significantly more positive anti–ficolin‐2 antibodies than those with nonproliferative LN. The combination of anti–ficolin‐2, anti–ficolin‐3, and anti‐C1q demonstrated a very high specificity (98%) for the diagnosis of active LN.
Conclusion
Our results support the usefulness of anti–ficolin‐2 as a complementary serologic biomarker for the diagnosis of active lupus with renal manifestations. |
| doi_str_mv | 10.1002/acr.23449 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_01696101v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2076933587</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4229-bbf0e974a3553a601b198b2cb244edcbd4ea77ebf2c7061fd3ed91f5b2204d593</originalsourceid><addsrcrecordid>eNp1kc1O3DAQxy3UChDlwAsgS72Uw4I_k_gYraAgrdqqpWpvlu1MWKMk3toO1d54BJ6RJ2nowiJV6lzmQz_9Z0Z_hI4oOaWEsDPj4injQqgdtM-opDNRyOrNthY_99BhSrdkCs6qiqtdtMcUEZLwch-5eszBDNnb0HhI-NrEG8h-uMEX3oXOD4_3Dwz7AX9bpwy9d3gxrsaEz-M6L6E3OaSp-2KyhyEn_MPnJa5d9neAP8FqGX326R1625ouweFzPkDfL86v55ezxeePV_N6MXOCMTWztiWgSmG4lNwUhFqqKsucZUJA42wjwJQl2Ja5khS0bTg0irbSMkZEIxU_QCcb3aXp9Cr63sS1Dsbry3qhn2aEFqqghN7Rif2wYVcx_BohZd375KDrzABhTJoqySSrVCEn9P0_6G0Y4zB9ohkpC8W5rMrX5S6GlCK02wso0U9G6cko_deoiT1-VhxtD82WfLFlAs42wG_fwfr_Srqef91I_gFP2JzY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2076933587</pqid></control><display><type>article</type><title>Autoantibodies Targeting Ficolin‐2 in Systemic Lupus Erythematosus Patients With Active Nephritis</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library All Journals</source><creator>Colliard, Sophie ; Jourde‐Chiche, Noémie ; Clavarino, Giovanna ; Sarrot‐Reynauld, Françoise ; Gout, Evelyne ; Deroux, Alban ; Fougere, Mélanie ; Bardin, Nathalie ; Bouillet, Laurence ; Cesbron, Jean‐Yves ; Thielens, Nicole M. ; Dumestre‐Pérard, Chantal</creator><creatorcontrib>Colliard, Sophie ; Jourde‐Chiche, Noémie ; Clavarino, Giovanna ; Sarrot‐Reynauld, Françoise ; Gout, Evelyne ; Deroux, Alban ; Fougere, Mélanie ; Bardin, Nathalie ; Bouillet, Laurence ; Cesbron, Jean‐Yves ; Thielens, Nicole M. ; Dumestre‐Pérard, Chantal</creatorcontrib><description>Objective
Systemic lupus erythematosus (SLE) is a multisystem inflammatory disease characterized by the production of various autoantibodies. The aim of this study was to investigate the presence of anti–ficolin‐2 antibodies in SLE patients and to evaluate the association between the levels of these autoantibodies, clinical manifestations, and disease activity.
Methods
This is a comparative study using a cohort of 165 SLE patients and 48 healthy subjects. SLE patients were further divided into 2 groups (low disease activity [SLE Disease Activity Index (SLEDAI) score ≤4, n = 88] and high disease activity [SLEDAI score >4, n = 77]). Clinical manifestations were defined according to the physician in charge. Active lupus nephritis (LN) was documented by kidney biopsy. Detection of anti–ficolin‐2 antibodies was performed by enzyme‐linked immunosorbent assay.
Results
Levels of anti–ficolin‐2 autoantibodies were significantly higher in SLE patients as compared to healthy subjects and associated with SLEDAI score. They were found to be positive in 61 of 165 SLE patients (37%). The presence of anti–ficolin‐2 antibodies was significantly related only to renal involvement, with a very high prevalence (86%) of anti–ficolin‐2 antibodies in SLE patients with active LN. Patients with active proliferative LN had significantly more positive anti–ficolin‐2 antibodies than those with nonproliferative LN. The combination of anti–ficolin‐2, anti–ficolin‐3, and anti‐C1q demonstrated a very high specificity (98%) for the diagnosis of active LN.
Conclusion
Our results support the usefulness of anti–ficolin‐2 as a complementary serologic biomarker for the diagnosis of active lupus with renal manifestations.</description><identifier>ISSN: 2151-464X</identifier><identifier>ISSN: 0893-7524</identifier><identifier>EISSN: 2151-4658</identifier><identifier>EISSN: 1529-0123</identifier><identifier>DOI: 10.1002/acr.23449</identifier><identifier>PMID: 29045037</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Adult ; Antibodies, Antinuclear - blood ; Autoantibodies ; Autoantibodies - blood ; Autoantibodies - immunology ; Biomarkers - metabolism ; Biopsy ; Biopsy, Needle ; Diagnosis ; Enzyme-Linked Immunosorbent Assay - methods ; Female ; Ficolins ; Human health and pathology ; Humans ; Immunoglobulins ; Immunohistochemistry ; Immunology ; Lectins - metabolism ; Life Sciences ; Lupus ; Lupus Erythematosus, Systemic - blood ; Lupus Erythematosus, Systemic - diagnosis ; Lupus Erythematosus, Systemic - epidemiology ; Lupus nephritis ; Lupus Nephritis - blood ; Lupus Nephritis - diagnosis ; Lupus Nephritis - epidemiology ; Male ; Middle Aged ; Nephritis ; Prevalence ; Rhumatology and musculoskeletal system ; Sensitivity and Specificity ; Severity of Illness Index ; Systemic lupus erythematosus</subject><ispartof>Arthritis care & research (2010), 2018-08, Vol.70 (8), p.1263-1268</ispartof><rights>2017, American College of Rheumatology</rights><rights>2017, American College of Rheumatology.</rights><rights>2018 American College of Rheumatology</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4229-bbf0e974a3553a601b198b2cb244edcbd4ea77ebf2c7061fd3ed91f5b2204d593</citedby><cites>FETCH-LOGICAL-c4229-bbf0e974a3553a601b198b2cb244edcbd4ea77ebf2c7061fd3ed91f5b2204d593</cites><orcidid>0000-0001-9315-1577 ; 0000-0003-3680-082X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Facr.23449$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Facr.23449$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,780,784,885,1416,27923,27924,45573,45574</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29045037$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-01696101$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Colliard, Sophie</creatorcontrib><creatorcontrib>Jourde‐Chiche, Noémie</creatorcontrib><creatorcontrib>Clavarino, Giovanna</creatorcontrib><creatorcontrib>Sarrot‐Reynauld, Françoise</creatorcontrib><creatorcontrib>Gout, Evelyne</creatorcontrib><creatorcontrib>Deroux, Alban</creatorcontrib><creatorcontrib>Fougere, Mélanie</creatorcontrib><creatorcontrib>Bardin, Nathalie</creatorcontrib><creatorcontrib>Bouillet, Laurence</creatorcontrib><creatorcontrib>Cesbron, Jean‐Yves</creatorcontrib><creatorcontrib>Thielens, Nicole M.</creatorcontrib><creatorcontrib>Dumestre‐Pérard, Chantal</creatorcontrib><title>Autoantibodies Targeting Ficolin‐2 in Systemic Lupus Erythematosus Patients With Active Nephritis</title><title>Arthritis care & research (2010)</title><addtitle>Arthritis Care Res (Hoboken)</addtitle><description>Objective
Systemic lupus erythematosus (SLE) is a multisystem inflammatory disease characterized by the production of various autoantibodies. The aim of this study was to investigate the presence of anti–ficolin‐2 antibodies in SLE patients and to evaluate the association between the levels of these autoantibodies, clinical manifestations, and disease activity.
Methods
This is a comparative study using a cohort of 165 SLE patients and 48 healthy subjects. SLE patients were further divided into 2 groups (low disease activity [SLE Disease Activity Index (SLEDAI) score ≤4, n = 88] and high disease activity [SLEDAI score >4, n = 77]). Clinical manifestations were defined according to the physician in charge. Active lupus nephritis (LN) was documented by kidney biopsy. Detection of anti–ficolin‐2 antibodies was performed by enzyme‐linked immunosorbent assay.
Results
Levels of anti–ficolin‐2 autoantibodies were significantly higher in SLE patients as compared to healthy subjects and associated with SLEDAI score. They were found to be positive in 61 of 165 SLE patients (37%). The presence of anti–ficolin‐2 antibodies was significantly related only to renal involvement, with a very high prevalence (86%) of anti–ficolin‐2 antibodies in SLE patients with active LN. Patients with active proliferative LN had significantly more positive anti–ficolin‐2 antibodies than those with nonproliferative LN. The combination of anti–ficolin‐2, anti–ficolin‐3, and anti‐C1q demonstrated a very high specificity (98%) for the diagnosis of active LN.
Conclusion
Our results support the usefulness of anti–ficolin‐2 as a complementary serologic biomarker for the diagnosis of active lupus with renal manifestations.</description><subject>Adult</subject><subject>Antibodies, Antinuclear - blood</subject><subject>Autoantibodies</subject><subject>Autoantibodies - blood</subject><subject>Autoantibodies - immunology</subject><subject>Biomarkers - metabolism</subject><subject>Biopsy</subject><subject>Biopsy, Needle</subject><subject>Diagnosis</subject><subject>Enzyme-Linked Immunosorbent Assay - methods</subject><subject>Female</subject><subject>Ficolins</subject><subject>Human health and pathology</subject><subject>Humans</subject><subject>Immunoglobulins</subject><subject>Immunohistochemistry</subject><subject>Immunology</subject><subject>Lectins - metabolism</subject><subject>Life Sciences</subject><subject>Lupus</subject><subject>Lupus Erythematosus, Systemic - blood</subject><subject>Lupus Erythematosus, Systemic - diagnosis</subject><subject>Lupus Erythematosus, Systemic - epidemiology</subject><subject>Lupus nephritis</subject><subject>Lupus Nephritis - blood</subject><subject>Lupus Nephritis - diagnosis</subject><subject>Lupus Nephritis - epidemiology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Nephritis</subject><subject>Prevalence</subject><subject>Rhumatology and musculoskeletal system</subject><subject>Sensitivity and Specificity</subject><subject>Severity of Illness Index</subject><subject>Systemic lupus erythematosus</subject><issn>2151-464X</issn><issn>0893-7524</issn><issn>2151-4658</issn><issn>1529-0123</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc1O3DAQxy3UChDlwAsgS72Uw4I_k_gYraAgrdqqpWpvlu1MWKMk3toO1d54BJ6RJ2nowiJV6lzmQz_9Z0Z_hI4oOaWEsDPj4injQqgdtM-opDNRyOrNthY_99BhSrdkCs6qiqtdtMcUEZLwch-5eszBDNnb0HhI-NrEG8h-uMEX3oXOD4_3Dwz7AX9bpwy9d3gxrsaEz-M6L6E3OaSp-2KyhyEn_MPnJa5d9neAP8FqGX326R1625ouweFzPkDfL86v55ezxeePV_N6MXOCMTWztiWgSmG4lNwUhFqqKsucZUJA42wjwJQl2Ja5khS0bTg0irbSMkZEIxU_QCcb3aXp9Cr63sS1Dsbry3qhn2aEFqqghN7Rif2wYVcx_BohZd375KDrzABhTJoqySSrVCEn9P0_6G0Y4zB9ohkpC8W5rMrX5S6GlCK02wso0U9G6cko_deoiT1-VhxtD82WfLFlAs42wG_fwfr_Srqef91I_gFP2JzY</recordid><startdate>201808</startdate><enddate>201808</enddate><creator>Colliard, Sophie</creator><creator>Jourde‐Chiche, Noémie</creator><creator>Clavarino, Giovanna</creator><creator>Sarrot‐Reynauld, Françoise</creator><creator>Gout, Evelyne</creator><creator>Deroux, Alban</creator><creator>Fougere, Mélanie</creator><creator>Bardin, Nathalie</creator><creator>Bouillet, Laurence</creator><creator>Cesbron, Jean‐Yves</creator><creator>Thielens, Nicole M.</creator><creator>Dumestre‐Pérard, Chantal</creator><general>Wiley Subscription Services, Inc</general><general>Wiley-Blackwell</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><orcidid>https://orcid.org/0000-0001-9315-1577</orcidid><orcidid>https://orcid.org/0000-0003-3680-082X</orcidid></search><sort><creationdate>201808</creationdate><title>Autoantibodies Targeting Ficolin‐2 in Systemic Lupus Erythematosus Patients With Active Nephritis</title><author>Colliard, Sophie ; Jourde‐Chiche, Noémie ; Clavarino, Giovanna ; Sarrot‐Reynauld, Françoise ; Gout, Evelyne ; Deroux, Alban ; Fougere, Mélanie ; Bardin, Nathalie ; Bouillet, Laurence ; Cesbron, Jean‐Yves ; Thielens, Nicole M. ; Dumestre‐Pérard, Chantal</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4229-bbf0e974a3553a601b198b2cb244edcbd4ea77ebf2c7061fd3ed91f5b2204d593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adult</topic><topic>Antibodies, Antinuclear - blood</topic><topic>Autoantibodies</topic><topic>Autoantibodies - blood</topic><topic>Autoantibodies - immunology</topic><topic>Biomarkers - metabolism</topic><topic>Biopsy</topic><topic>Biopsy, Needle</topic><topic>Diagnosis</topic><topic>Enzyme-Linked Immunosorbent Assay - methods</topic><topic>Female</topic><topic>Ficolins</topic><topic>Human health and pathology</topic><topic>Humans</topic><topic>Immunoglobulins</topic><topic>Immunohistochemistry</topic><topic>Immunology</topic><topic>Lectins - metabolism</topic><topic>Life Sciences</topic><topic>Lupus</topic><topic>Lupus Erythematosus, Systemic - blood</topic><topic>Lupus Erythematosus, Systemic - diagnosis</topic><topic>Lupus Erythematosus, Systemic - epidemiology</topic><topic>Lupus nephritis</topic><topic>Lupus Nephritis - blood</topic><topic>Lupus Nephritis - diagnosis</topic><topic>Lupus Nephritis - epidemiology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Nephritis</topic><topic>Prevalence</topic><topic>Rhumatology and musculoskeletal system</topic><topic>Sensitivity and Specificity</topic><topic>Severity of Illness Index</topic><topic>Systemic lupus erythematosus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Colliard, Sophie</creatorcontrib><creatorcontrib>Jourde‐Chiche, Noémie</creatorcontrib><creatorcontrib>Clavarino, Giovanna</creatorcontrib><creatorcontrib>Sarrot‐Reynauld, Françoise</creatorcontrib><creatorcontrib>Gout, Evelyne</creatorcontrib><creatorcontrib>Deroux, Alban</creatorcontrib><creatorcontrib>Fougere, Mélanie</creatorcontrib><creatorcontrib>Bardin, Nathalie</creatorcontrib><creatorcontrib>Bouillet, Laurence</creatorcontrib><creatorcontrib>Cesbron, Jean‐Yves</creatorcontrib><creatorcontrib>Thielens, Nicole M.</creatorcontrib><creatorcontrib>Dumestre‐Pérard, Chantal</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>Arthritis care & research (2010)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Colliard, Sophie</au><au>Jourde‐Chiche, Noémie</au><au>Clavarino, Giovanna</au><au>Sarrot‐Reynauld, Françoise</au><au>Gout, Evelyne</au><au>Deroux, Alban</au><au>Fougere, Mélanie</au><au>Bardin, Nathalie</au><au>Bouillet, Laurence</au><au>Cesbron, Jean‐Yves</au><au>Thielens, Nicole M.</au><au>Dumestre‐Pérard, Chantal</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Autoantibodies Targeting Ficolin‐2 in Systemic Lupus Erythematosus Patients With Active Nephritis</atitle><jtitle>Arthritis care & research (2010)</jtitle><addtitle>Arthritis Care Res (Hoboken)</addtitle><date>2018-08</date><risdate>2018</risdate><volume>70</volume><issue>8</issue><spage>1263</spage><epage>1268</epage><pages>1263-1268</pages><issn>2151-464X</issn><issn>0893-7524</issn><eissn>2151-4658</eissn><eissn>1529-0123</eissn><abstract>Objective
Systemic lupus erythematosus (SLE) is a multisystem inflammatory disease characterized by the production of various autoantibodies. The aim of this study was to investigate the presence of anti–ficolin‐2 antibodies in SLE patients and to evaluate the association between the levels of these autoantibodies, clinical manifestations, and disease activity.
Methods
This is a comparative study using a cohort of 165 SLE patients and 48 healthy subjects. SLE patients were further divided into 2 groups (low disease activity [SLE Disease Activity Index (SLEDAI) score ≤4, n = 88] and high disease activity [SLEDAI score >4, n = 77]). Clinical manifestations were defined according to the physician in charge. Active lupus nephritis (LN) was documented by kidney biopsy. Detection of anti–ficolin‐2 antibodies was performed by enzyme‐linked immunosorbent assay.
Results
Levels of anti–ficolin‐2 autoantibodies were significantly higher in SLE patients as compared to healthy subjects and associated with SLEDAI score. They were found to be positive in 61 of 165 SLE patients (37%). The presence of anti–ficolin‐2 antibodies was significantly related only to renal involvement, with a very high prevalence (86%) of anti–ficolin‐2 antibodies in SLE patients with active LN. Patients with active proliferative LN had significantly more positive anti–ficolin‐2 antibodies than those with nonproliferative LN. The combination of anti–ficolin‐2, anti–ficolin‐3, and anti‐C1q demonstrated a very high specificity (98%) for the diagnosis of active LN.
Conclusion
Our results support the usefulness of anti–ficolin‐2 as a complementary serologic biomarker for the diagnosis of active lupus with renal manifestations.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>29045037</pmid><doi>10.1002/acr.23449</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0001-9315-1577</orcidid><orcidid>https://orcid.org/0000-0003-3680-082X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2151-464X |
| ispartof | Arthritis care & research (2010), 2018-08, Vol.70 (8), p.1263-1268 |
| issn | 2151-464X 0893-7524 2151-4658 1529-0123 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_01696101v1 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Wiley Online Library All Journals |
| subjects | Adult Antibodies, Antinuclear - blood Autoantibodies Autoantibodies - blood Autoantibodies - immunology Biomarkers - metabolism Biopsy Biopsy, Needle Diagnosis Enzyme-Linked Immunosorbent Assay - methods Female Ficolins Human health and pathology Humans Immunoglobulins Immunohistochemistry Immunology Lectins - metabolism Life Sciences Lupus Lupus Erythematosus, Systemic - blood Lupus Erythematosus, Systemic - diagnosis Lupus Erythematosus, Systemic - epidemiology Lupus nephritis Lupus Nephritis - blood Lupus Nephritis - diagnosis Lupus Nephritis - epidemiology Male Middle Aged Nephritis Prevalence Rhumatology and musculoskeletal system Sensitivity and Specificity Severity of Illness Index Systemic lupus erythematosus |
| title | Autoantibodies Targeting Ficolin‐2 in Systemic Lupus Erythematosus Patients With Active Nephritis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T18%3A48%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Autoantibodies%20Targeting%20Ficolin%E2%80%902%20in%20Systemic%20Lupus%20Erythematosus%20Patients%20With%20Active%20Nephritis&rft.jtitle=Arthritis%20care%20&%20research%20(2010)&rft.au=Colliard,%20Sophie&rft.date=2018-08&rft.volume=70&rft.issue=8&rft.spage=1263&rft.epage=1268&rft.pages=1263-1268&rft.issn=2151-464X&rft.eissn=2151-4658&rft_id=info:doi/10.1002/acr.23449&rft_dat=%3Cproquest_hal_p%3E2076933587%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2076933587&rft_id=info:pmid/29045037&rfr_iscdi=true |